AstraZeneca Investor Day Presentation Deck
Imfinzi: extending IO leadership through portfolio combinations
26
Change in target lesion from baseline (%)
Probability of overall survival
1.0
0.8
0.6
0.4
120-
0.2
100-
80-
60-
40-
20
0
-20-
-60-
-80-
-100-
ADCs
POC: BEGONIA mBC 1L HER2-low/HR-
0
0
6
12
18
9
24
30
CTLA4
POC: POSEIDON (adv NSCLC)/Study 22 (HCC)/MEDI5752 Ph II
12
36
42
15
Time (weeks)
48
18
21
Time (months)
54
24
Best response
Partial response
Stable disease
RECIST progression.
New lesion
S22 (adv HCC):
Treme 300mg + Imfinzi vs. Imfinzi
60
27
66
30
72
33
36
39
CD73, NKG2A
POC: COAST - Stg III UR NSCLC (below) / Study 5 (PDAC)
PFS probability
1.0
0.9-
0.8-
0.7-
0.6-
0.5-
0.4-
0.3-
0.2-
0.1-
0
No. at risk
0
D 67
60
62
D+O
D+M
2
50
49
55
BIOSCIENCES
4
32
46
46
32
40
44
6
8
10
12
14
Time from randomisation (months)
20
37
41
TIGIT
>compugen
FROM CODE TO CURE T
72.7%
16
30
35
64.8%
39.2%
13
22
h
25
9
13
11
H|||
16
7
9
6
T
18
AZD2936
3
5
1
20
0
0
1
Imfinzi + domvanalimab
Phase III (PACIFIC-8)
Phase I/II (ARTEMIDE-01)
PARP inhibitor
POC: MEDIOLA BRCAwt PSR ovarian (below) / BAYOU (UC)
Best % change in
targetlesion size
100-
80-
60-
40-
20-
0
-20-
-40-
-60-
-80-
Survival Probability
-100
1.0-
ATR inhibitor
POC: PDX relapse - HUDSON adv NSCLC (below)/VIKTORY adv M
09-
08-
07-
06-
0.5-
04-
03-
02-
01-
Lynparza + Imfinzi + bevacizumab
00-
Confirmed ORR = 77.4% (95% CI 58.9-90.4)
Censored
ADCs antibody drug conjugates; CD73 = cluster of differentiation 73; NKG2A = natural killer group 2 member A; PARPI = poly (ADP-ribose) polymerase; CTLA4 = cytotoxic T-lymphocyte-associated protein 4; HCC = hepatocellular
carcinoma; TIGIT = T cell immunoreceptor with Ig and ITIM domains; ATR = ataxia telangiectasia and rad3-related; POC = proof of concept; UR = unresectable; NSCLC = non small cell lung cancer; BRCAwt = breast cancer gene
wildtype; PSR = platinum sensitive relapsed; PDAC = pancreatic ductal adenocarcinoma; UC = urothelial cancer; adv = advanced.
18
Time (months)
ORR = 87.1%
(95% CI 70.2-964)
Median DOR = 11.1 months
(IQR 7.4-164)
27
olaparib
danyatirsen
ceral asertib
oledumab
33
36
4View entire presentation